Bernard VERRIER
Equipe : Vecteurs colloïdaux et transport tissulaire
Courriel : bernard.verrier@ibcp.fr
Téléphone : +33(0)4-72-72-26-36
Statut : Directeur de recherches
2019
109. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation.
Coolen Al, Lacroix C, Mercier-gouy P, Delaune E, Monge C, Exposito Jy, Verrier B
(2019) Biomaterials 195 :23-37 
108. entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality.
Lamrayah M, Charriaud F, Hu S, Megy S, Terreux R, Verrier B
(2019) Int J Pharm 568 :118569-118569
107. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.
Linares-fernandez S, Lacroix C, Exposito Jy, Verrier B
(2019) Trends Mol Med :
2017
106. Tuning the Hydrophilic/Hydrophobic Balance to Control the Structure of Chitosan Films and Their Protein Release Behavior.
Becerra J, Sudre G, Royaud I, Montserret R, Verrier B, Rochas C, Delair T, David L
(2017) Aaps Pharmscitech 18 :1070-1083
105. Nanoparticle-Based Dressing: The Future of Wound Treatment?
Berthet M, Gauthier Y, Lacroix C, Verrier B, Monge C
(2017) Trends Biotechnol 35 :770-784
104. Innovative drug vehicle for local treatment of inflammatory skin diseases: Ex vivo and in vivo screening of five topical formulations containing poly(lactic acid) (PLA) nanoparticles.
Boisgard As, Lamrayah M, Dzikowski M, Salmon D, Kirilov P, Primard C, Pirot F, Fromy B, Verrier B
(2017) Eur J Pharm Biopharm 116 :51-60
103. Antibiotic incorporation in jet-sprayed nanofibrillar biodegradable scaffolds for wound healing.
Dzikowski M, Castanie N, Guedon A, Verrier B, Primard C, Sohier J
(2017) Int J Pharm :
102. Neutralizing and Targeting Properties of a New Set of ?4?7-Specific Antibodies Are Influenced by Their Isotype.
Girard A, Jelicic K, Van Ryk D, Rochereau N, Cicala C, Arthos J, Noailly B, Genin C, Verrier B, Laurant S, Razanajaoana-doll D, Pin Jj, Paul S
(2017) J Acquir Immune Defic Syndr 75 :118-127
101. Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.
Gutjahr A, Papagno L, Nicoli F, Lamoureux A, Vernejoul F, Lioux T, Gostick E, Price Da, Tiraby G, Perouzel E, Appay V, Verrier B, Paul S
(2017) J Immunol 198 :4205-4209
100. Improving bioassay sensitivity through immobilization of bio-probes onto reactive micelles.
Jimenez-sanchez G, Terrat C, Verrier B, Gigmes D, Trimaille T
(2017) Chem Commun (camb) 53 :8062-8065
99. Critical role for skin-derived migratory DCs and Langerhans cells in TFH and GC responses after intradermal immunization.
Levin C, Bonduelle O, Nuttens C, Primard C, Verrier B, Boissonnas A, Combadiere B
(2017) J Invest Dermatol 0 :0
98. Specific and Efficient Uptake of Surfactant-Free Poly(Lactic Acid) Nanovaccine Vehicles by Mucosal Dendritic Cells in Adult Zebrafish after Bath Immersion.
Resseguier J, Delaune E, Coolen Al, Levraud Jp, Boudinot P, Le Guellec D, Verrier B
(2017) Front Immunol 8 :190-190
97. Comparison of four different fuller’s earth formulations in skin decontamination.
Roul A, Le Ca, Gustin Mp, Clavaud E, Verrier B, Pirot F, Falson F
(2017) J Appl Toxicol :
96. Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.
Verrier B, Paul S, Terrat C, Bastide L, Ensinas A, Phelip C, Chanut B, Bulens-grassigny L, Jospin F, Guillon C
(2017) Front Immunol 8 :770-770
95. Ternary polysaccharide complexes: Colloidal drug delivery systems stabilized in physiological media.
Wu D, Ensinas A, Verrier B, Cuvillier A, Champier G, Paul S, Delair T
(2017) Carbohydr Polym 172 :265-274
2016
94. First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations.
Benjelloun F, Oruc Z, Thielens N, Verrier B, Champier G, Vincent N, Rochereau N, Girard A, Jospin F, Chanut B, Genin C, Cogne M, Paul S
(2016) J Immunol 197 :1979-88
93. Poly(Lactic Acid) Nanoparticles Targeting ?5?1 Integrin as Vaccine Delivery Vehicle, a Prospective Study.
Dalzon B, Lebas C, Jimenez G, Gutjahr A, Terrat C, Exposito Jy, Verrier B, Lethias C
(2016) Plos One 11 :e0167663-e0167663
92. Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.
Gutjahr A, Phelip C, Coolen Al, Monge C, Boisgard As, Paul S, Verrier B
(2016) Vaccines (basel) 4 :0
91. Controlled association and delivery of nanoparticles from jet-sprayed hybrid microfibrillar matrices.
Keloglu N, Verrier B, Trimaille T, Sohier J
(2016) Colloids Surf B Biointerfaces 140 :142-9
90. Evaluation of polylactic acid nanoparticles safety using Drosophila model.
Legaz S, Exposito Jy, Lethias C, Viginier B, Terzian C, Verrier B
(2016) Nanotoxicology 10 :1136-43
89. Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands.
Pavot V, Climent N, Rochereau N, Garcia F, Genin C, Tiraby G, Vernejoul F, Perouzel E, Lioux T, Verrier B, Paul S
(2016) Biomaterials 75 :327-339
88. Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity.
Rochereau N, Pavot V, Verrier B, Jospin F, Ensinas A, Genin C, Corthesy B, Paul S
(2016) J Allergy Clin Immunol 137 :214-222
87. Composite wound dressings of pectin and gelatin with aloe vera and curcumin as bioactive agents.
Tummalapalli M, Berthet M, Verrier B, Deopura Bl, Alam Ms, Gupta B
(2016) Int J Biol Macromol 82 :104-13
86. Drug loaded composite oxidized pectin and gelatin networks for accelerated wound healing.
Tummalapalli M, Berthet M, Verrier B, Deopura Bl, Alam Ms, Gupta B
(2016) Int J Pharm 505 :234-45
85. Zinc-Stabilized Chitosan-Chondroitin Sulfate Nanocomplexes for HIV-1 Infection Inhibition Application.
Wu D, Ensinas A, Verrier B, Primard C, Cuvillier A, Champier G, Paul S, Delair T
(2016) Mol Pharm 13 :3279-91
2015
84. A Novel Alpha Cardiac Actin (ACTC1) Mutation Mapping to a Domain in Close Contact with Myosin Heavy Chain Leads to a Variety of Congenital Heart Defects, Arrhythmia and Possibly Midline Defects.
Augiere C, Megy S, El Malti R, Boland A, El Zein L, Verrier B, Megarbane A, Deleuze Jf, Bouvagnet P
(2015) Plos One 10 :e0127903-e0127903
83. Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.
Jimenez-sanchez G, Pavot V, Chane-haong C, Handke N, Terrat C, Gigmes D, Trimaille T, Verrier B
(2015) Pharm Res 32 :311-20
82. A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in cellulo.
Legaz S, Exposito Jy, Borel A, Candusso Mp, Megy S, Montserret R, Lahaye V, Terzian C, Verrier B
(2015) Protein Expr Purif 113 :94-101
81. Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells.
Rochereau N, Pavot V, Verrier B, Ensinas A, Genin C, Corthesy B, Paul S
(2015) Eur J Immunol 45 :773-9
80. New easy handling and sampling device for bioavailability screening of topical formulations.
Salmon D, Gilbert E, Gioia B, Haftek M, Pivot C, Verrier B, Pirot F
(2015) Eur J Dermatol 25 Suppl 1 :23-9
79. Micelle-Based Adjuvants for Subunit Vaccine Delivery.
Trimaille T, Verrier B
(2015) Vaccines (basel) 3 :803-13
2014
78. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.
Climent N, Munier S, Pique N, Garcia F, Pavot V, Primard C, Casanova V, Gatell Jm, Verrier B, Gallart T
(2014) Vaccine 32 :6266-76
77. Co-delivery of Antigen p24 and NOD-ligands by PLA Nanoparticles to Human Dendritic Cells Promote Highly Functional HIV-1-Specific T-cell Responses.
Climent N, Pavot V, Garcia F, Lioux T, Perouzel E, Primard C, Paul S, Gatell Jm, Plana M, Verrier B, Gallart T
(2014) Aids Res Hum Retroviruses 30 Suppl 1 :A240-1
76. Skin Migratory APCs Fine-tune Lymph Node Microenvironment for the Generation of T Follicular Helper Cells and Mucosal Immunity.
Levin C, Nuttens C, Bonduelle O, Perrin H, Verrier B, Fazilleau N, Combadiere B
(2014) Aids Res Hum Retroviruses 30 Suppl 1 :A126-7
75. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
Pavot V, Berthet M, Resseguier J, Legaz S, Handke N, Gilbert Sc, Paul S, Verrier B
(2014) Nanomedicine (lond) 9 :2703-18
74. Recent progress in HIV vaccines inducing mucosal immune responses.
Pavot V, Rochereau N, Lawrence P, Girard Mp, Genin C, Verrier B, Paul S
(2014) Aids 28 :1701-18
73. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity.
Pavot V, Rochereau N, Resseguier J, Gutjahr A, Genin C, Tiraby G, Perouzel E, Lioux T, Vernejoul F, Verrier B, Paul S
(2014) J Immunol 193 :5781-5
72. Chimeric Nod2/TLR2 Ligand Amplifies HIV-1 Gag p24-specific Mucosal and Systemic Immune Responses after Sub Cutaneous Immunization in Mice.
Phelip C, Pavot V, Rochereau N, Perouzel E, Lioux T, Tiraby G, Primard C, Paul S, Verrier B
(2014) Aids Res Hum Retroviruses 30 Suppl 1 :A195-A195
71. Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells.
Rancan F, Amselgruber S, Hadam S, Munier S, Pavot V, Verrier B, Hackbarth S, Combadiere B, Blume-peytavi U, Vogt A
(2014) J Control Release 176 :115-22
70. Large-scale nucleotide optimization of simian immunodeficiency virus reduces its capacity to stimulate type I interferon in vitro.
Vabret N, Bailly-bechet M, Lepelley A, Najburg V, Schwartz O, Verrier B, Tangy F
(2014) J Virol 88 :4161-72
2013
69. Secretory IgA specific for MPER can protect from HIV-1 infection in vitro.
Benjelloun F, Dawood R, Urcuqui-inchima S, Rochereau N, Chanut B, Verrier B, Lucht F, Genin C, Paul S
(2013) Aids 27 :1992-5
68. Lysine-tagged peptide coupling onto polylactide nanoparticles coated with activated ester-based amphiphilic copolymer: a route to highly peptide-functionalized biodegradable carriers.
Handke N, Ficheux D, Rollet M, Delair T, Mabrouk K, Bertin D, Gigmes D, Verrier B, Trimaille T
(2013) Colloids Surf B Biointerfaces 103 :298-303
67. Elaboration of glycopolymer-functionalized micelles from an N-vinylpyrrolidone/lactide-based reactive copolymer platform.
Handke N, Lahaye V, Bertin D, Delair T, Verrier B, Gigmes D, Trimaille T
(2013) Macromol Biosci 13 :1213-20
66. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties.
Pavot V, Rochereau N, Primard C, Genin C, Perouzel E, Lioux T, Paul S, Verrier B
(2013) J Control Release 167 :60-7
65. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.
Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, De Koker S
(2013) Mol Ther 21 :251-9
64. Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells.
Rochereau N, Drocourt D, Perouzel E, Pavot V, Redelinghuys P, Brown Gd, Tiraby G, Roblin X, Verrier B, Genin C, Corthesy B, Paul S
(2013) Plos Biol 11 :e1001658-e1001658
2012
63. Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.
Benjelloun F, Lawrence P, Verrier B, Genin C, Paul S
(2012) J Virol 86 :13152-63
62. Cutting edge: Protective effect of CX3CR1+ dendritic cells in a vaccinia virus pulmonary infection model.
Bonduelle O, Duffy D, Verrier B, Combadiere C, Combadiere B
(2012) J Immunol 188 :952-6
61. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells.
Duffy D, Perrin H, Abadie V, Benhabiles N, Boissonnas A, Liard C, Descours B, Reboulleau D, Bonduelle O, Verrier B, Van Rooijen N, Combadiere C, Combadiere B
(2012) Immunity 37 :917-29
60. New insights in mucosal vaccine development.
Pavot V, Rochereau N, Genin C, Verrier B, Paul S
(2012) Vaccine 30 :142-54
59. Stability of polylactic acid particles and release of fluorochromes upon topical application on human skin explants.
Rancan F, Todorova A, Hadam S, Papakostas D, Luciani E, Graf C, Gernert U, Ruhl E, Verrier B, Sterry W, Blume-peytavi U, Vogt A
(2012) Eur J Pharm Biopharm 80 :76-84
58. The biased nucleotide composition of HIV-1 triggers type I interferon response and correlates with subtype D increased pathogenicity.
Vabret N, Bailly-bechet M, Najburg V, Muller-trutwin M, Verrier B, Tangy F
(2012) Plos One 7 :e33502-e33502
2011
57. Elaboration of Densely Functionalized Polylactide Nanoparticles from N-Acryloxysuccinimide-Based Block Copolymers
Handke N, Trimaille T, Luciani E, Rollet M, Delair T, Verrier B, Bertin D, Gigmes D,
(2011) Journal Of Polymer Science Part A-polymer Chemistry 49 :1341-1350
56. Intradermal immunization triggers epidermal langerhans-cell mobilization required For CD8 T-cell immune responses
Liard C, Menier S, Joulin-giet A, Vogt A, Bonduelle O, Hadam S, Duffy D, Verrier B, Combadiere B
(2011) Journal Of Investigative Dermatology 131 :S101-S101
55. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses.
Liard C, Munier S, Arias M, Joulin-giet A, Bonduelle O, Duffy D, Shattock Rj, Verrier B, Combadiere B
(2011) Vaccine 29 :6379-91
54. Poly(lactic acid) nanoparticles [Nps of PLA] as anti-tumoral vaccination vehicles
Munier S, Borel A, Gauthier Y, Delair T, Verrier B
(2011) Bulletin Du Cancer 98 :S68-S69
53. Biodegradable poly lactic acid particles for transcutaneous drug delivery and skin cell targeting
Rancan F, Amselgruber S, Hadam S, Munier S, Delair T, Verrier B, Sterry W, Blume-peytavi U, Vogt A
(2011) Experimental Dermatology 20 :208-209
52. Phenotypic localization of distinct DC subsets in mouse Peyer Patch.
Rochereau N, Verrier B, Pin Jj, Genin C, Paul S
(2011) Vaccine 29 :3655-61
51. Phenotypic localization of distinct DC subsets in mouse Peyer Patch
Rochereau N, Verrier B, Pin Jj, Genin C, Paul S
(2011) Vaccine 29 :3655-3661
2010
50. Capture of enveloped viruses using polymer tentacles containing magnetic latex particles.
Arkhis A, Elaissari A, Delair T, Verrier B, Mandrand B
(2010) J Biomed Nanotechnol 6 :28-36
49. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.
Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, De Lamballerie X, Suhrbier A, Cherel Y, Le Grand R, Roques P
(2010) J Clin Invest 120 :894-906
48. Polylactic acid (PLA) particles for hair follicle targeting: controlled release of incorporated fluorochromes after skin contact
Todorova A, Rancan F, Luciani E, Graf C, Verrier B, Sterry W, Vogt A
(2010) Experimental Dermatology 19 :596-596
47. Polysaccharide-based vaccine delivery systems: Macromolecular assembly, interactions with antigen presenting cells, and in vivo immunomonitoring.
Weber C, Drogoz A, David L, Domard A, Charles Mh, Verrier B, Delair T
(2010) J Biomed Mater Res A 93 :1322-34
46. Co-adsorption of TLR3 ligand and HIV-1 antigens increase potency of particulate vaccine vehicles based on chitosan or poly (lactic acid) backbone
Weber C, Verrier B
(2010) Aids Research And Human Retroviruses 26 :A39-A39
2009
45. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.
Abadie V, Bonduelle O, Duffy D, Parizot C, Verrier B, Combadiere B
(2009) Plos One 4 :e8159-e8159
44. Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1.
Beaumont E, Vendrame D, Verrier B, Roch E, Biron F, Barin F, Mammano F, Brand D
(2009) J Virol 83 :9875-89
43. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice.
Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O, Boissonnas A, Sterry W, Verrier B, Blume-peytavi U, Combadiere B
(2009) J Invest Dermatol 129 :1156-64
42. PLA-nanoparticles as a drug delivery system for topical dermatotherapy
Papakostas D, Rancan F, Hadam S, Hackbarth S, Delair T, Verrier B, Sterry W, Blume-peytavi U, Vogt A
(2009) Experimental Dermatology 18 :305-305
41. Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients.
Puissant-lubrano B, Combadiere B, Duffy D, Wincker N, Frachette Mj, Ait-mohand H, Verrier B, Katlama C, Autran B
(2009) Vaccine 27 :3576-83
2008
40. Towards biocompatible vaccine delivery systems: interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen.
Drogoz A, Munier S, Verrier B, David L, Domard A, Delair T
(2008) Biomacromolecules 9 :583-91
2007
39. Generation of specific Th1 and CD8+ T-cell responses by immunization with mouse CD8+ dendritic cells loaded with HIV-1 viral lysate or envelope glycoproteins.
Aline F, Brand D, Bout D, Pierre J, Fouquenet D, Verrier B, Dimier-poisson I
(2007) Microbes Infect 9 :536-43
38. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route.
Cleret A, Quesnel-hellmann A, Vallon-eberhard A, Verrier B, Jung S, Vidal D, Mathieu J, Tournier Jn
(2007) J Immunol 178 :7994-8001
37. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits.
Guillon C, Mayol K, Terrat C, Compagnon C, Primard C, Charles Mh, Delair T, Munier S, Verrier B
(2007) Vaccine 25 :7491-501
36. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.
Lambele M, Labrosse B, Roch E, Moreau A, Verrier B, Barin F, Roingeard P, Mammano F, Brand D
(2007) J Virol 81 :125-40
35. Characterization of the antibody response elicited by HIV-1 Env glycomutants in rabbits.
Reynard F, Willkomm N, Fatmi A, Vallon-eberhard A, Verrier B, Bedin F
(2007) Vaccine 25 :535-46
2006
34. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models.
Ataman-onal Y, Munier S, Ganee A, Terrat C, Durand Py, Battail N, Martinon F, Le Grand R, Charles Mh, Delair T, Verrier B
(2006) J Control Release 112 :175-85
33. Replacement of HIV-1 Env natural cleavage sites by aphtovirus 2A peptides
Bedin F , Fatmi A , Reynard F , Vallon A , Durand Py , Verrier B
(2006) Journal Of Clinical Virology 36 :S51-S51
32. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins.
Van Gulck Er, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, Colebunders R, Van Den Bosch G, Van Bockstaele Dr, Van Tendeloo Vf, Allard S, Verrier B, Maranon C, Hoeffel G, Hosmalin A, Berneman Zn, Vanham G
(2006) Blood 107 :1818-27
2005
31. Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope.
Cheynet V, Ruggieri A, Oriol G, Blond Jl, Boson B, Vachot L, Verrier B, Cosset Fl, Mallet F
(2005) J Virol 79 :5585-93
30. [Mechanisms of resistance to sexual transmission of HIV-1].
Eberhard A, Ponceau B, Biron F, Verrier B
(2005) Med Mal Infect 35 :517-24
29. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties.
Munier S, Messai I, Delair T, Verrier B, Ataman-onal Y
(2005) Colloids Surf B Biointerfaces 43 :163-73
2004
28. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope.
Dacheux L, Moreau A, Ataman-onal Y, Biron F, Verrier B, Barin F
(2004) J Virol 78 :12625-37
27. HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity.
Reynard F, Fatmi A, Verrier B, Bedin F
(2004) Virology 324 :90-102
26. Short communication: retrospective study to time the introduction of HIV type 1 non-B subtypes in Lyon, France, using env genes obtained from primary infection samples.
Vachot L, Ataman-onal Y, Terrat C, Durand Py, Ponceau B, Biron F, Verrier B
(2004) Aids Res Hum Retroviruses 20 :687-91
2003
25. Elaboration of poly(ethyleneimine) coated poly(D,L-lactic acid) particles. Effect of ionic strength on the surface properties and DNA binding capabilities
Messai I, Munier S, Ataman-onal Y, Verrier B, Delair T
(2003) Colloids And Surfaces B-biointerfaces 32 :293-305
2002
24. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B, Le Grand R, Ataman-onal Y, Terrat C, Guillon C, Durand Py, Hurtrel B, Aubertin Am, Sutter G, Erfle V, Girard M
(2002) Dna Cell Biol 21 :653-8
2000
23. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients.
Biron F, Ponceau B, Bouhour D, Boibieux A, Verrier B, Peyramond D
(2000) J Acquir Immune Defic Syndr 25 :329-36
1999
22. Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization.
Fayolle J, Verrier B, Buckland R, Wild Tf
(1999) J Virol 73 :787-90
21. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA.
Giraud A, Ataman-onal Y, Battail N, Piga N, Brand D, Mandrand B, Verrier B
(1999) J Virol Methods 79 :75-84
1998
20. Evolution of HIV antibody testing
Ataman-onal Y, Biron F, Verrier B
(1998) Medecine Et Maladies Infectieuses 28 :496-504
19. Quantitative and discriminative detection of individual HIV-1 mRNA subspecies by an RNase mapping assay.
Mary C, Akaoka H, Verrier B
(1998) Methods Mol Biol 92 :89-100
1997
18. Transmission of the human immunodeficiency virus and the hepatitis C virus.
Biron F, Verrier B, Peyramond D
(1997) N Engl J Med 337 :348-9
17. [HTLV I virus infection disclosed by recurrent scabies associated with genital condylomatosis].
Dupin M, Guennoc B, Zimmermann R, Martin L, Verrier B, Flechaire A, Combemale P
(1997) Ann Med Interne (paris) 148 :406-7
1996
16. Imbalanced expression of glutamate-glutamine cycle enzymes induced by human T-cell lymphotropic virus type 1 Tax protein in cultivated astrocytes.
Akaoka H, Hardin-pouzet H, Bernard A, Verrier B, Belin Mf, Giraudon P
(1996) J Virol 70 :8727-36
15. At an early differentiation stage, the dendritic cells Langerhans cells are infectable by HIV-1 in an in vitro infection model
Charbonnier As, Dezutterdambuvant C, Fiers Mm, Jacquet C, Verrier B, Mallet F, Mandrand B, Schmitt D
(1996) Journal Of Investigative Dermatology 107 :P46-P46
14. In vitro HIV1 infection of CD34+ progenitor-derived dendritic/Langerhans cells at different stages of their differentiation in the presence of GM-CSF/TNF alpha.
Charbonnier As, Verrier B, Jacquet C, Massacrier C, Fiers Mm, Mallet F, Dezutter-dambuyant C, Schmitt D
(1996) Res Virol 147 :89-95
1995
13. IN-VITRO HIV-1 INFECTION OF CD34+ PRECURSORS OF DENDRITIC CELLS LANGERHANS CELLS AT THE EARLY DIFFERENTIATION
Charbonnier As, Verrier B, Jacquet C, Massacrier C, Fiers Mm, Mallet F, Dezutterdambuyant C, Schmitt D
(1995) Journal Of Investigative Dermatology 105 :499-499
12. Induction of MMP9 (92 kDa gelatinase) activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-I.
Giraudon P, Thomasset N, Bernard A, Verrier B, Belin Mf
(1995) Eur J Neurosci 7 :841-8
11. Cell surface phenotypic changes induced in H9 T cells chronically infected with HTLV type I or HIV type 1 or coinfected with the two viruses.
Noraz N, Verrier B, Fraisier C, Desgranges C
(1995) Aids Res Hum Retroviruses 11 :145-54
1994
10. Transient adult T-cell leukemia/lymphoma picture during varicella infection in an HTLV-1 carrier.
D’incan M, Combemale P, Verrier B, Garin D, Audoly G, Brunot J, Desgranges C, Flechaire A
(1994) Leukemia 8 :682-7
9. Quantitative and discriminative detection of individual HIV-1 mRNA subspecies by an RNAse mapping assay.
Mary C, Telles Jn, Cheynet V, Oriol G, Mallet F, Mandrand B, Verrier B
(1994) J Virol Methods 49 :9-23
1993
8. Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification.
Cheynet V, Verrier B, Mallet F
(1993) Protein Expr Purif 4 :367-72
7. CLINICAL AND BIOLOGICAL FEATURES OF PRIMARY HIV-INFECTION – REVIEW OF PUBLISHED LITERATURE
Denoray G, Biron F, Verrier B, Boibieux A, Bailly Ma, Bertrand Jl, Peyramond D
(1993) Medecine Et Maladies Infectieuses 23 :643-652
6. DETECTION OF MULTIPLY-SPLICED MESSENGER-RNAS AND REGULATORY PROTEINS DURING HIV-INFECTION
Gruters Ra, Mary C, Cheynet V, Oriol G, Mallet F, Verrier B
(1993) Journal Of Cellular Biochemistry Suppl. 17E :47-47
1992
5. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins.
Bonnefoy-berard N, Verrier B, Vincent C, Revillard Jp
(1992) Immunology 77 :61-7
4. Monocyte-independent T-cell activation by polyclonal antithymocyte globulins.
Bonnefoy-berard N, Vincent C, Verrier B, Revillard Jp
(1992) Cell Immunol 143 :272-83
1991
3. Four regulatory elements in the human c-fos promoter mediate transactivation by HTLV-1 Tax protein.
Alexandre C, Verrier B
(1991) Oncogene 6 :543-51
2. RESEARCH OF HTLV1-LIKE RETROVIRAL SEQUENCES IN PSORIASIS
Bernard F, Bassetseguin N, Verrier B, Mion H, Guilhou Jj
(1991) Journal Of Investigative Dermatology 96 :640-640
1. Retrovirus-mediated gene transfer of a human c-fos cDNA into mouse bone marrow stromal cells.
Roux P, Verrier B, Klein B, Niccolino M, Marty L, Alexandre C, Piechaczyk M
(1991) Oncogene 6 :2155-60
